Aida Pharmaceuticals has said that its upcoming Rh-Apo2L cancer drug has been named as a "New and High-Tech Transforming Products of 2007" by the Shanghai New High Technology Service Center (SNHTSC), a special government commercialization division backed by the Shanghai Municipal Government.
This designation will allow Rh-Apo2L to have preferential policies during the commercialization process after Aida completes China's State Food and Drug Administration ("SFDA") clinical testing of the product.
The stated role of the SNHTSC is to be a clearinghouse that allows the Chinese government to evaluate and narrow down technology candidates that have the greatest potential for national and global commercialization. Candidates must go through a strict appraisal by SNHTSC's expert committee, comprised of ten experts and government officials from differing fields of study.
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in China.